BG
Bindu George
U.S. Food and Drug Administration, US Food and Drug Administration White Oak Campus, University of Maryland Medical System, MedStar Harbor Hospital, Private Practice
0000-0002-3237-1960
Employment
-
U.S. Food and Drug Administration Physician2022 - Present
-
US Food and Drug Administration White Oak Campus Supervisory Physician2016 - 2022
-
U.S. Food and Drug Administration Supervisory Physician2015 - 2016
-
U.S. Food and Drug Administration Team Lead2009 - 2015
-
US Food and Drug Administration White Oak Campus Medical Officer2007 - 2009
-
Private Practice Physician2004 - 2007
Education
-
University of Maryland Medical System M.D.2001 - 2004
-
MedStar Harbor Hospital M.D.1997 - 2000
-
Government Stanley Medical College
Projects & Funding
Projects & funding information is unavailable.
Publications (9)
- FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma Save
- Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project Save
- FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma. Save
- Summary of US Food and Drug Administration Chimeric Antigen Receptor T-Cell Biologics License Application Approvals From a Statistical Perspective. Save
- FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. Save
- Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. Save
- FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma. Save
- FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. Save
- Regulation of biologic oncology products in the FDA׳s Center for Biologics Evaluation and Research. Save